Signal Messages in Pediatric Practice

Безопасность и риск фармакотерапии

卷:6

G. V. Kutekhova¹  N. Yu. Velts¹  E. O. Zhuravleva¹  M. A. Darmostukova¹  I. I. Snegireva¹  E. V. Shubnikova¹  R. N. Alyautdin¹ 

[1] Scientific Centre for Expert Evaluation of Medicinal Products, Moscow;

关键词: loratadine;    desloratadine;    weight gain;    signal;    pharmacovigilance;    drug safety;    pediatrics;    allergy;   

DOI  :  10.30895/2312-7821-2018-6-4-180-186

来源: DOAJ

【 摘 要 】

Abstract. Detection and analysis of drug safety signals in children is a mandatory part of pharmacovigilance. The criteria for evaluating signals of adverse effects were considered. Spontaneous reports databases as a source for detecting signaling information about adverse reactions, including in children were used. More than 17.5 million cases of adverse reactions identified in WHO global database of individual case safety reports — VigiBase which was detected since 1968 in 120 countries — members of the WHO Drug Treatment Control Program. Of these, 1.5 million cases of adverse reactions occur in childhood. Objective: search and analysis for signal information in the post-marketing period of the use of drugs in children to increase the safety of pharmacotherapy in pediatric practice. Results: а causal relationship between desloratadine and weight gain was detected. Desloratadine is an active metabolite of loratadine so the researchers have considered reports on desloratadine and also on loratadine. In VigiBase there are reports of weight gain when taking desloratadine (44 messages) and loratadine (115 messages) in 2016. Among them, 22 reports on weight gain in children from 2 to 11 years. The Pharmacovigilance Risk Assessment Committee of the European Medical Agency (PRAC EMA) recommended marketing authorization holders to add an information about weight gain in children in prescribing information of drugs which contains desloratadine and loratadine. In September 2017, the Committee on Drugs for Human Use, following a review and analysis of VigiBase, approved the recommendations of PRAC EMA. Appropriate changes were made to the instructions for medical use for loratadine tablets. Conclusions. These results confirm the importance of long post-marketing studies, the results of which will provide significant assistance in improving the safety of pharmacotherapy in children.

【 授权许可】

Unknown